Trials / Completed
CompletedNCT06199934
Effectiveness of BNT162b2 Formulations Using State Vaccine Registry and Insurance Claims Data
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 19,853,610 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to learn about how well different versions of the Pfizer-BioNTech COVID-19 vaccine (called BNT162b2) work at preventing death, severe COVID-19 that requires a trip to the hospital, and overall use of healthcare resources, such as needing to go the doctor or urgent care due to illness. Pfizer is not enrolling any participants for this study. Instead, existing data from different health data sources will be used to help answer the scientific questions Pfizer is interested in learning more about.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Vaccination | BNT162b2 vaccination |
Timeline
- Start date
- 2023-09-11
- Primary completion
- 2024-07-31
- Completion
- 2024-07-31
- First posted
- 2024-01-10
- Last updated
- 2025-09-10
- Results posted
- 2025-09-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06199934. Inclusion in this directory is not an endorsement.